CytoQuest™ Universal Circulating Tumor Cell CSV CSV CD45 Antibody Kit

Catalog # KA4818 Size 1 Kit

Applications



Immunofluorescence (Circulating Tumor Cell)

Representative images of EMT transformed CTC (white arrow) and WBC from prostate cancer patient. CSV EMT CTCs were detected by using immunofluorescence staining for CSV (FITC, green), CD45 (PE, orange) and Nucleus (Hoechst, blue).

Specification

Product Description	CytoQuest™ Universal Circulating Tumor Cell CSV CSV CD45 Antibody Kit contains antibodies for immobilization and immunostaining of circulating tumor cells.
Instrument Requirement	CytoQuest™ CR
Chip Requirement	CytoChipNano
Supplied Product	Kit content: 1. Anti-CSV capturing antibody (Biotin): Biotin conjugated Anti-CSV antibody for CTC capturing. 2. Anti-CSV detecting antibody (FITC): FITC conjugated Anti-CSV antibody for CTC detection. 3. Anti-CD45 detecting antibody (PE): PE conjugated Anti-CD45 antibody for CTC detection. *Reagents are sufficient for 20 assays using recommended protocol.
Regulatory Status	For research use only (RUO)

Storage Instruction	Store Anti-CSV detecting antibody (FITC), Anti-CD45 detecting antibody (PE) at 4°C. Store Anti-CSV capturing antibody (Biotin) plate and 50X Antibody Dilution Buffer (50X ADB) at -20° C. Aliquot to avoid repeated freezing and thawing.
Note	Cell-Surface Vimentin (CSV) detecting antibody is best used before cell fixation and permeabilizatio n. If fixation is required, please use Abnova's Special Fixative. Cell-Surface Vimentin (CSV) antibody is a pending MD Anderson patent which has been exclusively licensed to Abnova Corporation.

Applications

- Immunofluorescence (Circulating Tumor Cell)

  Representative images of EMT transformed CTC (white arrow) and WBC from prostate cancer patient. CSV EMT CTCs were detected by using immunofluorescence staining for CSV (FITC, green), CD45 (PE, orange) and Nucleus (Hoechst, blue).

Publication Reference

- Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer.

  Chia-Lin Hsu, Tzu-Hsiu Tsai, Chun-Kai Huang, Ching-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, Sheng-Yuan Ruan, Kuan-Yu Chen, Jin-Yuan Shih, Pan-Chyr Yang.

  Lung Cancer 2021 Jun; 156:50.

  Application: IF, Human, Human circulating tumor cells